Majdan M, Ksiazek A, Swatowski A
Kliniki Nefrologii Akademii Medycznej w Lublinie.
Pol Arch Med Wewn. 1995 Jan;93(1):58-62.
After 1/2 year long clinical observation 50 maintenance hemodialyzed patients were divided into two groups. Group I consisted of patients with haemoglobin concentration exceeded 9.5 g/dl and hematocrit above 30%, not treated with rHuEPO. Patients of group II permanently or periodically required treatment of rHuEPO to maintain haematological parameters written above. Then mean maintaining dose of rHuEPO was 5,500 units weekly. The concentrations of haemoglobin, albumin, creatinine, transferrin, KT/V and body mass index (BMI) handled as parameters of quality of dialysis therapy (PQD) of two groups were compared. Lack of treatment with rHuEPO in hemodialyzed patients of group I, with adequate Hb concentration, does not change significantly PQD in comparison with patients of group II treated with rHuEPO.
经过半年的临床观察，50名维持性血液透析患者被分为两组。第一组患者血红蛋白浓度超过9.5g/dl，血细胞比容高于30%，未接受重组人促红细胞生成素（rHuEPO）治疗。第二组患者永久性或定期需要rHuEPO治疗以维持上述血液学参数。当时rHuEPO的平均维持剂量为每周5500单位。比较了两组作为透析治疗质量参数（PQD）的血红蛋白、白蛋白、肌酐、转铁蛋白、KT/V和体重指数（BMI）的浓度。第一组血红蛋白浓度充足的血液透析患者未接受rHuEPO治疗，与接受rHuEPO治疗的第二组患者相比，其PQD没有显著变化。
